Smith+Nephew announced the results of a systematic review and meta-analysis of comparative trials to determine the efficacy of its IODOSORB 0.9% Cadexomer Iodine Range on chronic wounds versus standard care specific to the wound type. The review found that wounds were more than twice as likely to completely heal with IODOSORB Range than with standard care, and significantly greater reductions in wound area were observed after 8 weeks of treatment versus standard care. Use of IODOSORB Range helped reduce barriers to healing such as exudate, slough, pus, debris and bacteria, significantly reducing wound area and increasing the chance of healing chronic wounds compared with standard care. Venous leg ulcers (VLUs), diabetic foot ulcers (DFUs) and pressure ulcers were included in the study. The review included 13 studies comparing IODOSORB Dressings with standard care, summarising the clinical evidence supporting IODOSORB Dressings in wound bed preparation. In addition to patient comorbidities, there were a number of local factors that could act as barriers to wound healing. These included excessive exudate, cellular debris/pus/slough, and the presence of biofilm or infection. IODOSORB Dressing is a unique topical antimicrobial with dual-action, offering the benefits of a broad-spectrum, sustained-activity antimicrobial agent in combination with desloughing and fluid-handling properties, making it effective against biofilm in vitro and in vivo.